DxUpClose, Inc. is an early stage in vitro diagnostic company developing a novel medical device to help physicians better care for their patients suffering from an infectious disease.
Infectious diseases and the rise of antibiotic resistant bacteria pose a serious threat to global public health. Antibiotic resistant bacteria already kill hundreds of thousands a year globally. According to the CDC, antibiotic resistant bacteria cause more than 2,300,000 illnesses and 37,000 deaths in the US alone. Research indicates that 4 out of 5 Americans are prescribed antibiotics each year and that antibiotics are incorrectly prescribed between 30% and 50% of the time.
Our point-of-care rapid diagnostic device goal is to provide identification and antibiotic susceptibility test results such that physicians can prescribe the right antibiotic the first time to: